Overview

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Status:
Unknown status

Trial end date:
2017-09-01

Target enrollment:

Participant gender:

Summary

This phase 2 study is designed to evaluate the safety and tolerability activity of TH-302 and dexamethasone with or without bortezomib or pomalidomide in subjects with relapsed/refractory multiple myeloma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Threshold Pharmaceuticals

Treatments:

BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Phosphoramide Mustards
Pomalidomide
Thalidomide